Companies in this industry manufacture drugs, therapies, vaccines, and other products based on genetically manipulated compounds. Major companies include US-based Amgen, Biogen, Genentech (owned by Switzerland-based Roche), Gilead Sciences, and Monsanto, as well as CSL (Australia), Merck KGaA (Germany), Novo Nordisk (Denmark), and the biotech research arms of major international pharmaceutical companies such as Sanofi (France).
The global biotechnology industry generates total revenue of about $330 billion, according to Global Market Insights. Top regions for biotechnology include the US and Europe. Emerging markets include Australia, Canada, China, India, Singapore, and Brazil.
The US biotechnology product manufacturing industry includes about 2,800 companies with combined annual revenue of around $120 billion, according to Ernst & Young. Because many drugs are now developed using biotechnology, the biotechnology and pharmaceutical industries overlap considerably. Pharmaceutical Manufacturing is covered in a separate industry report.
Demand for biotechnology products is driven by insurers' willingness to pay for new medical treatments, the global need to produce more food for a rapidly expanding population, and scientists' desire to find solutions for complex scientific and medical issues. Funding for biotech research is often provided by venture capital funds hoping to cash in on new products. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential products is so large, small biotechnology companies can co-exist successfully with large ones if they have expertise in a particular line of...